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What’s already known about this topic?  
 
• Reported outcome measure instruments for hidradenitis suppurativa (HS) are numerous 
and diverse with 30 instruments recently found in 12 randomised trials.  
• This diverse use of instruments limits the possibility to perform evidence synthesis and 
may produce outcome reporting bias. 
• A Core Outcomes Set (COS) is an agreed minimum set of outcomes that should be 
measured and reported in all clinical trials.  
 
 
What does this study add? 
 
• The study used an international and multi-stakeholder approach, involving patients, 
dermatologists, surgeons, the pharmaceutical industry and medical regulators. 
• Two consensus meetings, in Europe and North America, considered potential HS core 
domains, within a nominal group theory structure  
• Seven potential core domains were put forward to the subsequent online Delphi: disease 
course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain, and global 
assessment.   
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Abstract 
 
BackgroundA Core Outcomes Set (COS) is an agreed minimum set of outcomes that should be 
measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) 
has no agreed upon COS.  A central aspect in the COS development process is to generate and 
prioritise a list of candidate items and domains. There is no existing gold standard methodology, 
but in most COS processes the domains are defined by the steering group. In this study, we used a 
modified approach in which the Delphi participants worked side by side on creating the domains 
at two consensus meetings. These meetings took place in September and October 2016 in Vienna 
and New York respectively and the results are reported here. Objectives:The main objectives were 
to consider which items from a long list of candidate items to exclude and which to cluster into 
outcome domains. Methods:The study used an international and multi-stakeholder approach, 
involving patients, dermatologists, surgeons, the pharmaceutical industry and medical regulators.  
The study format was a combination of formal presentations and small group work based on 
nominal group theory to generate consensus. Results:41 individuals from 13 countries and four 
continents participated. Nine items were excluded and there was consensus to propose seven 
domains: disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain, 
and global assessment. Conclusions: The HISTORIC consensus meetings I and II will be followed by 
further online Delphi rounds to finalise the core domain set, building on the work of the in-person 
consensus meetings. 
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INTRODUCTION 
Development of evidence-based and consensus-driven outcome measures are necessary to ensure 
that study results are comparable to permit meta-analyses and hence better inform healthcare 
decisions. In consequence, consensus on outcomes is a prerequisite for patients to receive the 
benefits of top level evidence based medicine. Hidradenitis suppurativa (HS) is a chronic, 
inflammatory skin disease, characterised by repeated outbreaks of painful inflamed nodules or 
boils in the apocrine gland-bearing regions (axillae, genital area, groin, breasts and perianal 
region).1,2 The estimated prevalence is 1-4 % worldwide.3-5 HS is associated with significant 
disability due to pain and subsequent loss of mobility.6 Interventions for HS are diverse and 
include topical treatment, systemic antibiotics, anti-inflammatory therapy, biologics and surgical 
therapy including laser surgery. There is a need for continuing research on therapies since the 
level of evidence for existing treatments is low, suggesting a particular need for trials.8  
 
Clinical trials should have well-defined primary and secondary outcomes to answer questions 
generated by the main hypotheses. A Core Outcome Set (COS) is an agreed minimum set of 
outcomes that should be measured and reported in all clinical trials of a specific disease or trial 
population, a recommendation of what should be measured and reported in all clinical trials.9 
Once a COS is defined, the next step is to achieve consensus on the instruments most suitable to 
measure each core domain.10 This selection process includes evaluation of the quality of the 
instruments, assessing their validity, reliability, responsiveness to change and feasibility.11  
Like most diseases, HS has no agreed upon COS and the reported outcome measure instruments 
are numerous. In a recent systematic review, the authors identified a total of 30 outcome measure 
instruments in 12 RCTs and the quality of studies looking at validity of the instruments was 
generally low.12 Consequently trialists and researchers use various instruments, which may or may 
not be representative of the most important aspects of the disease. In addition, the heterogeneity 
and lack of consensus regarding use of outcome measure instruments limits the possibility to 
perform evidence synthesis, including meta-analysis,8 and likely leads to outcome reporting bias 
because of selective reporting of more favourable outcomes. Empirical evidence of this 
phenomenon has been highlighted in the literature.13  
Based on these existing problems within HS outcome measures the HIdradenitis 
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SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) was formed as a 
collaboration between the International Dermatology Outcome Measures (IDEOM) initiative, the 
Cochrane Skin Group - Core Outcome Set Initiative (CSG-COUSIN) and Zealand University Hospital, 
Roskilde. 
The first HISTORIC goal was to develop a COS for HS clinical trials, reducing the risk of 
heterogeneity in instruments and outcome reporting bias and ensuring that researchers report on 
outcomes that are relevant to all major stakeholders.14,15. The intention is that the COS for efficacy 
measures should help guide all HS clinical trials on a global basis, covering both medical and 
surgical trials.   
A central aspect in the COS development process is to generate and prioritise a list of 
candidate items and domains. There is no existing gold standard methodology, but in most COS 
development processes the domains/outcomes are defined by the steering group based on results 
from literature reviews and qualitative studies in relevant stakeholder groups.16-18  In our COS 
development process, the steering group decided that a wider set of HS stakeholders should have 
the chance to vote by e-Delphi on 56 nominal items to help guide formation of candidate domains.   
After the first two online Delphi rounds the Delphi participants were then invited to 
take part in two consensus meetings, where patients and health care professionals (HCPs) worked 
side by side on creating the domains together with members of the steering committee. This 
method permitted inclusion of opinions from a wider set of patients and other Delphi participants 
in the important phase of domain formation from candidate items. The consensus meetings took 
place in September and October 2016 in Vienna, and New York respectively, and the results are 
reported here. 
 
Aims 
The aims of the 1st consensus meeting were to: 
• Review results of the first two online Delphi rounds 
• Discuss whether any items could be removed from the list of potential items 
• Discuss grouping of items into domains 
• Discuss appropriate names for the created domains 
 
The aim of the 2nd consensus meeting was to obtain a North American perspective on the same 
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four points including the results of the first meeting. Specific questions addressed were: 
• Should any items excluded at the first meeting be retained? 
• Do all items fit in their domains? 
• Should any combined items form their own domain? 
• Is the name for each domain appropriate? 
 
MATERIALS AND METHODS   
 
Initial steps  
An overview of our COS development methodology highlighting the contribution of the in-person 
consensus meetings can be found in figure 1.  Initiatives including Core Outcome Measures in 
Effectiveness Trials (COMET),14 Outcome Measures in Rheumatology (OMERACT)19 and 
Harmonizing Outcome Measures for Eczema (HOME)10 provided methodological guidance that 
was used and adapted by our HS COS group.  Prior to the current study a list of 56 candidate items 
was identified by combining three data sets: (1) a systematic review of literature, (2) US and 
Danish qualitative interview studies involving HS patients, and (3) an online HCP item generation 
survey. More details for these phases can be found in our COS development protocol.20  
In brief, the online Delphi exercise involved 94 participants (42 HS patients and 52 
HCPs) from 19 countries across four continents. In the first two Delphi rounds, participants voted 
on an unsorted list of candidate items in terms of their importance in being measured as 
outcomes in all future HS trials. The results of the first two rounds were then used to inform the 
structure of two consensus meetings, which are reported here. 
 
Study design 
The study was international and multi-professional involving patients, dermatologists, cutaneous 
surgeons, general surgeons, industry representatives and drug regulatory authorities.  The study 
took place at two face-to-face consensus meetings, in September 2016 in Vienna and in October 
2016 at an IDEOM meeting in New York.  The locations were planned for both Europe and North 
America to ensure that European and North American patient and HCP opinions from both 
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continents were incorporated. The meetings were planned by the HISTORIC steering group, 
consisting of researchers, HS clinicians and a patient research partner.20 
 
Meeting participants 
All Delphi participants from the e-Delphi surveys were invited to attend either the first or the 
second meeting. If attendance in person was not possible, they were invited to join the Vienna 
meeting via a Skype connection. Identification and purposive sampling of the e-Delphi 
participants is described in the study protocol.20 A few additional individuals who had shown an 
interest in joining the initiative were invited to take part in the second meeting. Our aim was to 
maintain a 1:1 ratio of patients: HCPs if possible. 
 
Study procedures 
An overview of the study procedures can be found in figure 2. Both consensus meetings had the 
same overall structure.  The structure consisted of initial formal presentations, followed by small 
group work and subsequent plenary sessions, based on nominal group theory.21 The spoken 
language was English. Introductory presentations included a description of the HISTORIC 
collaboration, a summary of the need for a COS for HS clinical trials, and results from the first two 
rounds of the online Delphi survey.20 Background information about how the candidate items 
were identified was also provided, together with an introduction to the small group work designed 
to generate consensus using nominal group theory.  It was stressed that the views of all 
participants at the meeting, both patients and HCPs, were of equal importance.  
The introductory presentations were followed by a series of small group sessions (6 
in the first meeting and 3 in the second meeting). For each task, two small groups worked 
independently and in parallel, supervised by neutral facilitators. Both facilitators were medical 
doctors and PhD students studying HS, who were not voting in the E-Delphi surveys. The neutral 
facilitators encouraged contributions from quieter group members. Group members were 
switched between each session to ensure that different combinations of patients and HCPs were 
formed; however, each small group contained at least two patients so that HCPs did not dominate 
the discussion. 
 Physical cards, one for each item, were placed on the table for each small group to 
provide a visual aid for the discussion. On the front of each card was the name and a description of 
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an item and on the reverse side were summary statistics of the votes cast for the item in the 
preceding e-Delphi exercise, subdivided by patients and HCPs. Each small group session lasted 20-
40 minutes.  
Results from each of the two small groups were presented to all participants in 
subsequent plenary sessions, stimulating discussion if there were differences between the groups. 
Consensus was sought by discussion, without preceding voting.  If consensus was not reached 
through discussion then no decision was imposed, for example when discussing an item for 
possible exclusion if no consensus was reached then the item was retained.   
The two meetings were similar in structure but differed slightly in the required tasks.  
Tasks for the first meeting were ranking of the items in order of priority, identifying items that 
could be excluded, grouping of remaining items into domains and ranking of domains in order of 
priority. The second meeting was asked to mirror the first by considering if any excluded items 
should be retained, checking whether participants agreed with the item combinations that were 
put forward by the first meeting to form domains, and considering whether the domain names 
were appropriate.  
 
Next steps  
Findings from both meetings will be used to form the basis of subsequent online Delphi surveys to 
obtain consensus from the wider group of stakeholders involved in the process. Based on our 
protocol, all decisions taken at the meetings need to be confirmed by the larger Delphi group 
before they are implemented because only a sub-set of the e-Delphi group could contribute to the 
in-person meetings.  
  
RESULTS  
 
Participants 
A list of study participants subdivided by stakeholder group, country and gender can be found in 
table 1. 
The HISTORIC consensus meeting I had 19 participants (5 patients, 14 HCPs) from 11 countries 
across four continents, the majority being European. The HISTORIC consensus meeting II had 25 
participants (6 patients, 19 HCPs), the majority being North American.  
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The 11 participating HS patients represented six different patient organisations. One 
additional Canadian patient participated in the first meeting via a Skype  connection. The 
participating HCPs were dermatologists (n=14), dermatologic surgeons (n=5), FDA representatives 
(n=2), pharmaceutical industry representatives (n=2), epidemiologists (n=3), and non-voting (in e-
Delphi) steering group members/facilitators (n=4). For comparison, the 52 HCPs included in the E-
Delphi round one were dermatologists (n=41), dermatologic surgeons (n=5), medical regulators 
(n=1), nurses (n=4) and pharmaceutical industry representatives (n=1). 
 
Excluded items 
The comprehensive list of unsorted items (n=57) that the participants evaluated is shown in Table 
2. Nine items were marked for exclusion the HISTORIC consensus meeting I due to lack of 
relevance, being unrelated to measurement of disease severity, or not directly linked to the 
disease. A list of the nine items that the participants agreed to exclude, together with arguments 
for their exclusion can be found in Table 3.  Some participating HCPs spoke in favour of excluding 
coping, itch and fatigue, but participating patients did not approve and the items were retained.   
At the HISTORIC consensus meeting II , there was consensus that all of the items 
identified at the first meeting were appropriately designated for exclusion. However, it was agreed 
that the biomarker item should be marked as an area of specific future research interest. It was 
noted that if, in the future, a biomarker is proven to be strongly related to disease activity or 
treatment response then the biomarker item/domain should be reconsidered for inclusion in the 
core domain set.  
 
Grouping of items into domains and naming domains  
Creation of potential domains was achieved by three small group and plenary sessions at the 
HISTORIC consensus meeting I, producing consensus to group the items into nine domains (Table 
4). These domains and their contributing items were reviewed during two sessions at the 
HISTORIC consensus meeting II. HISTORIC consensus meeting II participants recommended 
switching, the `number of chronic areas´ item from the `physical signs´ domain to the `disease 
course´ domain, as the item would be reported by the patient rather than being measured by the 
physician.  It was highlighted that the term ‘chronic’ in this context needs to be defined further 
and this issue was marked as a future task for the HISTORIC project. The group provisionally 
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agreed that ‘chronic’ relates to a duration of at least 6 weeks.   
Both working groups at consensus meeting II independently agreed to rename the 
`decreased mobility’ item as `physical functioning’ and to combine this domain with the 
`psychological-social´ domain to form a `HS-specific quality of life´ domain. Participants 
emphasized that it is crucial that this domain should capture the specific aspects of the patient’s 
quality of life that are affected by HS, so a generic health related quality of life domain would not 
be sufficient.  
Another recommendation from meeting II was to group together the `patient global 
assessment´ and `physician global assessment´ domains to produce a single `global assessment´ 
domain encompassing both the patient and HCP perspective. This fusion and the global 
assessment items/domains themselves were heavily debated.  Some participants felt that the 
global assessments should be excluded altogether, because, by definition, global assessment 
provides a relatively non-specific overview of disease severity. Others spoke in favour of global 
assessments because they considered a global anchor to be very useful. Another argument in 
favour of retaining global assessments is that these domains are considered important by the FDA. 
Creation of a single ‘global assessment’ domain was suggested by a group member and supported 
by the rest of the group based on the concept that both the patient and HCP global perspectives 
are important and should be assessed in a similar manner. 
 After HISTORIC consensus meeting II, there was consensus to suggest seven core 
domains: disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain, 
and global assessments (Table 5). 
 
DISCUSSION  
In total, 41 stakeholders including patients, dermatologists, (dermatologic) surgeons, 
epidemiologists, statisticians, pharmaceutical industry representatives and drug regulatory 
representatives participated in the HISTORIC consensus meetings I and II. Important progress was 
made towards reaching global consensus on core outcomes for HS clinical trials. Seven potential 
core domains were put forward for consideration by the larger e-Delphi consensus group in 
subsequent E-Delphi surveys.  
Our study differs from other COS processes in that our domains were developed 
through in-person discussion, combining items from a comprehensive list of candidate items. This 
 11 
discussion was guided by votes cast in preceding e-Delphi surveys. In most previous studies, 
domains are created by the steering committee alone without broader dialogue with Delphi 
participants before the first round of the Delphi survey is launched. The concept of involving more 
patients and other Delphi participants in the creation of the domains is based on the principle of 
inclusivity, in keeping with the philosophy of our HISTORIC initiative.  Feedback from stakeholders 
was very positive and the general view was that an inclusive approach is important to ensure 
relevance to patients and subsequent global acceptance and use of the HS COS by clinical trial 
designers.  
One methodological limitation is that it was not possible to have all e-Delphi 
participants present at the meetings, and therefore it was not possible to incorporate everyone’s 
opinion in the formation of domains. To mitigate for this, the next step will be to ask the larger e-
Delphi group if they agree with the decisions made at the meetings in an evaluation and 
confirmation survey. After this, the next planned steps are to perform two additional E-Delphi 
rounds. The results from these rounds will finalise the core domain set, having built on the work 
from our in-person consensus meetings. 
Another limitation to the study is that we did not reach our aim of a 1:1 ratio of 
participating patients:HCPs. Most of the participating patients were however representatives from 
HS patient associations and were able to represent a full cross-section of HS patients in terms of 
demographics and disease severity. Meeting facilitators ensured that patients provided equal 
input compared to HCPs, even though they were outnumbered by the HCPs, by encouraging 
patient involvement in every aspect of the discussion.   
With the present study, we have come a lot closer to global consensus on a COS for 
HS research. The number of randomised controlled trials of HS therapy is still limited. However, 
interest in the disease is growing and the number of trials planned is considerable. The 
development of a COS is thus particularly timely for HS, and a HS COS should substantially improve 
future HS trial design. 
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FIGURE LEGENDS  
 
Fig 1. Summary of the HS Core domain development process, with a highlight of the part described in this 
study  
 
Fig 2. Summary of study procedures. See text for details.  
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 Participants 
HISTORIC 
Consensus meeting I 
Vienna 
HISTORIC 
Consensus meeting II 
New York 
Subdivided by stakeholder group (n)     
Patients 5 6 
Health care professionals:     
Dermatologist HS experts 8 8 
Cutaneous surgeons  3 2 
Statisticians 0 1 
Epidemiologists 0 2 
FDA representatives 0 2 
Pharmaceutical industry  0 2 
Steering group/facilitators not included above 3 2 
      
Patients subdivided by country (n)     
Belgium  1 0 
Canada* 0 3 
Denmark 1 0 
United Kingdom 3 3 
USA 0 0 
      
HCPs subdivided by country (n)     
Australia  1 0 
Canada 0 4 
Denmark 3 2 
Germany 1 0 
Israel 0 1 
Malaysia 2 0 
Poland  1 0 
Sweden 1 0 
the Netherlands  3 0 
United Kingdom 1 1 
USA 1 11 
      
Subdivided by gender     
Male n (%) 11(58%)  9(36%) 
      
Total number  19 25 
*One patient from Canada participated in the first meeting via a Skype connection 
 
Table 1 Study participants subdivided by stakeholder group, country and gender. Three members from the 
HISTORIC steering group (From UK, USA and Denmark) participated in both meetings and are thus 
represented twice in the table. 
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Table 2 List of all items included in the Delphi exercise (item 57 included after the first round). The Help text was shown with each 
item in the e-Delphi as well as on the cards that were used for the small group work at the meetings. The items numbers generated 
at random before round one of the e-Delphi.  
Item   Help text Item   Help text 
1 Biomarkers 
Measures of disease presence or activity in blood 
samples 
30 Dyspigmentation Changes (lighter or darker) to the normal colour of your skin 
2 Drainage Secretion, blood, stains, suppuration 31 Anatomic location Body areas and number of body areas involved 
3 Edema Swelling of the skin 32 
Number of 
inflamed nodules 
Number of red, painful or tender nodules 
4 Economic burden 
Economic burden to the patient related to the disease 
(e.g., doctor appointments, surgery, medication), 
management (e.g., bandages, pads, or diet), time lost   
33 
Psychological 
functioning  
Feelings of depression, apathy, loneliness, suicidal thoughts. 
Feelings of irritation, anxiety, stress  
5 Coping Being able to handle (cope with) having the disease 34 
Health related  
Quality of life 
Perceived physical, mental and social health over time 
6 Odour Unpleasant odour 35 Number of fistulae Number of connections to skin surface   
7 
Satisfaction with 
treatment 
Satisfaction with effectiveness; time spent on treatment 36 Pain Pain 
8 
Adverse effects 
of surgical 
treatments 
All types of side effects from surgical treatments (e.g. 
bleeding, infection, contractures) 
37 Cognition 
Impact on concentration (e.g. at work or at school, or in leisure 
activities) 
9 Number of cysts 
Number of sac-like pockets under the skin which 
contain fluid or debris from the skin 
38 Fatigue Physical weariness sometimes combined with mental weariness 
10 Comorbidities 
Associated diseases e.g. metabolic syndrome,  PCOS or 
other inflammatory diseases 
39 Cosmesis 
Visual appearance of a person's skin from his/her own 
perspective related to the disease and surgery for the disease 
11 Intimacy 
Impact on sexual having desire or feeling desired, pain 
during sexual activity, abstaining from sex, fear of being 
rejected 
40 
Patient global 
evaluation 
Overall assessment of the disease from the perspective of the 
patient himself or herself, alone and without the influence of 
anyone else 
12 
Ability to work or 
study 
Ability to work or study, ability to gain or keep 
employment, influence on type of job or study, time off 
from work or study, impact on career 
41 Washing or Bathing 
Ability to wash or bathe oneself; having to frequently wash or 
bathe oneself 
13 
Adverse effects 
of medical 
treatments 
All types of side effects from medical treatments 42 Ulceration  Absence of upper layers of the skin forming an ulcer 
14 
Number of non- 
inflamed nodules 
Number of skin coloured nodules which may not be 
painful or tender 
43 
Physician global 
evaluation 
Overall assessment of the disease from the perspective of the 
physician alone 
15 Itch Itch 44 
Number of sinus 
tracts 
Number of tunnel-like connections between lesions 
16 
Self-treatment, 
not prescribed 
Self-treatment which is not prescribed (e.g. self-incision 
to obtain pain relief, placing ice cubes or warm 
compresses on boils 
45 
Scarring from 
surgery 
Scars resulting from surgery 
17 
Number of 
abscesses 
Number of collections of pus (sterile or infected) 46 Compliance  A patient's adherence to a recommended course of treatment 
18 
Total lesion 
count 
Total number of all types of lesions 47 
Satisfaction with 
care 
Access to care, satisfaction with  the doctor´s knowledge of 
disease, quality of care, feeling supported by medical personnel 
19 
Psychosocial 
functioning  
Feelings of being accepted by others, nervous to be in 
public, withdrawn from relationships  
48 Independence Need to be independent, not to dependent on others 
20 Scarring from HS Scar formation in involved areas 49 
Time to post-op 
recovery 
Time to healing after surgery 
21 
Need for 
treatment and 
bandages 
Requirements for prescribed treatment, e.g. acute 
treatment,  pain killers, topic treatment, in-hospital 
treatment and bandages 
50 
Clothing 
restrictions 
Impact on choice of clothing (e.g. choosing clothes that do not 
irritate lesions, that cover lesions, that cover stains 
22 Surface area Area of the skin surface involved 51 Flare frequency Frequency of flares 
23 
Impact on close 
relationships  
Impact on relationship to partner or family member, 
neglect of family, poor understanding of disease by 
family 
52 
Inflammatory lesion 
count 
Total number of all red, painful or tender lesions (abscesses or 
inflamed nodules) 
24 
Time to 
recurrence 
Time to reappearance  of activity, such as after surgery 
or after ending medical therapy 
53 Comedones 
Appearance of small "blackheads" on the surface of the skin 
formed by the blockage of pores 
25 
Emotional well-
being 
Feelings of powerlessness, embarrassment, low self-
esteem  
54 
Constitutional 
symptoms 
The experience of one or more symptom(s) associated with the 
development of new lesions (e.g. fatigue, fever-like sensation, 
headache) 
26 
Decreased 
mobility 
Decreased mobility, skin tightness, may be associated 
with restrictions in exercising, walking, reaching out, 
standing, sitting, activities of daily living (e.g. 
housework) 
55 Erythema Redness of the skin 
27 
Satisfaction with 
social roles 
Satisfaction with oneself as a partner, parent, family 
member, friend, or colleague 
56 Sleep-disturbance Difficulty sleeping, inability to sleep, poor quality of sleep 
28 
Progression of 
course 
Worsening of disease, prevention of worsening 57 
Number of chronic 
areas  
Number of chronic areas open for more than 6 weeks 
29 
Recreation and 
leisure activity 
Interference with leisure/recreational activities (e.g., 
sports, do-it-yourself, playing instruments, scouting, 
hiking or outdoor life). Interference with planning of 
such activities 
   
 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Items marked for exclusion at HISTORIC consensus meeting I and II with the arguments for their exclusion  
  
Item (help text) Reasoning for exclusion (agreed by patients and HCPs) 
Self-treatment – not prescribed 
(Self-treatment which is not prescribed 
(e.g. self-incision to obtain pain relief, 
placing ice cubes or warm compresses on 
boils) 
Too non-specific, difficult to measure 
Biomarkers 
(Measures of disease presence or activity 
in blood samples) 
For HS, there is no biomarker proven to be strongly related to disease 
activity and treatment response 
Cosmesis 
(Visual appearance of a person’s skin 
from his/her own perspective related to 
the disease and surgery for the disease) 
Participating patients felt that this item was not as important as other 
items, and felt that cosmesis was coved by other items such as scarring 
and number of sinus tracts 
Washing or bathing 
(Ability to wash or bathe oneself; having 
to frequently wash or bathe oneself) 
Very individual. Could be an instrument to measure drainage, but would 
then be covered by the drainage item 
Comedones 
(Appearance of small “blackheads” on the 
surface of the skin formed by the 
blockage of pores) 
Participants, especially patients, felt that this item was not important 
enough to be a core outcome for trials 
Dyspigmentation 
(Changes (lighter or darker) to the normal 
colour of your skin) 
Participants, especially patients, felt that this item was not important 
enough to be a core outcome for trials 
Satisfaction with care 
(Satisfaction with oneself as a partner, 
parent, family member, friend, or 
colleague) 
Not likely to be directly affected as an outcome by any intervention.  
Often depends on individual doctor-patient relationships 
Economic burden 
(Economic burden to the patient related 
to the disease (e.g., doctor appointments, 
surgery, medication), management (e.g., 
bandages, pads, or diet), time lost) 
Difficult to measure, varies a lot from country to country, in trials 
treatment expenses are covered 
Comorbidities 
(Associated diseases e.g. metabolic 
syndrome, PCOS or other inflammatory 
diseases) 
Not fair to include comorbidities as core outcomes as some 
treatments might improve HS but not the comorbidities. 
Comorbidities that might result from treatment should be captured as 
adverse events 
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Table 4 Results of HISTORIC consensus meeting I in Vienna: list of created domains and their included items  
 
 
Domain Included items (help text) 
1. Disease course 
Progression of course (Worsening of disease, prevention of worsening) 
Time to recurrence (Time to reappearance  of activity, such as after surgery or after ending medical 
therapy) 
Flare frequency and duration (Frequency and duration of flares) 
2. Physical signs 
Total lesion count (Total number of all types of lesions)  
Inflammatory lesion count  (Total number of all red, painful or tender lesions (abscesses or inflamed 
nodules)) 
Number of inflamed nodules (Number of skin coloured nodules which may not be painful or tender) 
Number of non-inflamed nodules (Number of skin coloured nodules which may not be painful or tender) 
Number of abscesses (Number of collections of pus (sterile or infected)) 
Number of fistulae (Number of connections to skin surface)  
Number of sinus tracts (Number of tunnel-like connections between lesions) 
Ulceration  (Absence of upper layers of the skin forming an ulcer) 
Edema (Swelling of the skin) 
Number of cyst (Number of sac-like pockets under the skin which contain fluid or debris from the skin) 
Erythema (Redness of the skin) 
Anatomic location (Body areas and number of body areas involved) 
Surface area (Area of the skin surface involved) 
Scarring from HS (Scar formation in involved areas) 
Number of chronic areas (Number of chronic areas open for more than 6 weeks) 
3. Psychological-social 
Coping (Being able to handle (cope with) having the disease) 
Emotional well-being (Feelings of powerlessness, embarrassment, low self-esteem) 
Sleep-disturbance (Difficulty sleeping, inability to sleep, poor quality of sleep) 
Ability to work or study (Ability to work or study, ability to gain or keep employment, influence on type of 
job or study, time off from work or study, impact on career) 
Independence (Need to be independent, not to dependent on others) 
Satisfaction with social roles (Satisfaction with oneself as a partner, parent, family member, friend, or 
colleague) 
Psychosocial functioning (Feelings of being accepted by others, nervous to be in public, withdrawn from 
relationships)  
Psychological functioning (Feelings of depression, apathy, loneliness, suicidal thoughts. Feelings of 
irritation, anxiety, stress) 
Intimacy (Impact on sexual having desire or feeling desired, pain during sexual activity, abstaining from sex, 
fear of being rejected) 
Recreation (Interference with leisure/recreational activities (e.g., sports, do-it-yourself, playing 
instruments, scouting, hiking or outdoor life). Interference with planning of such activities) 
Impact on close relationships (Impact on relationship to partner or family member, neglect of family, poor 
understanding of disease by family) 
Cognition (Impact on concentration (e.g. at work or at school, or in leisure activities)) 
Clothing restrictions (Impact on choice of clothing (e.g. choosing clothes that do not irritate lesions, that 
cover lesions, that cover stains) 
4. Satisfaction 
Satisfaction with treatment (Satisfaction with effectiveness; time spent on treatment) 
Compliance (A patient's adherence to a recommended course of treatment) 
Adverse effects of medical treatments (All types of side effects from medical treatments)  
Adverse effects of surgical treatments (All types of side effects from surgical treatments (e.g. bleeding, 
infection, contractures) 
Scarring from surgery (Scars resulting from surgery) 
Time to post-op recovery (Time to healing after surgery)  
Need for treatment and bandages (Requirements for prescribed treatment, e.g. acute treatment,  pain 
killers, topic treatment, in-hospital treatment and bandages) 
5. Symptoms 
Constitutional/prodromal (The experience of one or more symptom(s) associated with the development of 
new lesions (e.g. fatigue, fever-like sensation, headache) 
Fatigue (Physical weariness sometimes combined with mental weariness) 
Itch (Itch) 
Odour (Unpleasant odour) 
Drainage (Secretion, blood, stains, suppuration) 
6. Decreased mobility 
Decreased mobility (decreased mobility, skin tightness may be associated with restrictions in exercising, 
walking, reaching out, standing, sitting, activities of daily living (e.g. housework) 
7. Pain Pain 
8. Patient global assessment 
Patient global assessment (Overall assessment of the disease from the perspective of the patient himself 
or herself, alone and without the influence of anyone else) 
9. Physician global assessment 
Physician global assessment (Overall assessment of the disease from the perspective of the physician 
alone) 
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*Domains/items that were changed or moved at HISTORIC consensus meeting II compared with consensus meeting I  
Table 5 Results of HISTORIC consensus meeting II: list of created domains and their included items  
Domain Included items (help text) 
1. Disease course 
Progression of course (Worsening of disease, prevention of worsening) 
Time to recurrence (Time to reappearance  of activity, such as after surgery or after ending medical 
therapy) 
Flare frequency and duration (Frequency and duration of flares) 
Number of chronic areas* (Number of chronic areas open for more than 6 weeks) 
2. Physical signs 
Total lesion count (Total number of all types of lesions)  
Inflammatory lesion count  (Total number of all red, painful or tender lesions (abscesses or inflamed 
nodules)) 
Number of inflamed nodules (Number of skin coloured nodules which may not be painful or tender) 
Number of non-inflamed nodules (Number of skin coloured nodules which may not be painful or tender) 
Number of abscesses (Number of collections of pus (sterile or infected)) 
Number of fistulae (Number of connections to skin surface)  
Number of sinus tracts (Number of tunnel-like connections between lesions) 
Ulceration  (Absence of upper layers of the skin forming an ulcer) 
Edema (Swelling of the skin) 
Number of cyst (Number of sac-like pockets under the skin which contain fluid or debris from the skin) 
Erythema (Redness of the skin) 
Anatomic location (Body areas and number of body areas involved) 
Surface area (Area of the skin surface involved) 
Scarring from HS (Scar formation in involved areas) 
3.  HS specific quality of 
life* 
Coping (Being able to handle (cope with) having the disease) 
Emotional well-being (Feelings of powerlessness, embarrassment, low self-esteem) 
Sleep-disturbance (Difficulty sleeping, inability to sleep, poor quality of sleep) 
Ability to work or study (Ability to work or study, ability to gain or keep employment, influence on type of 
job or study, time off from work or study, impact on career) 
Independence (Need to be independent, not to dependent on others) 
Satisfaction with social roles (Satisfaction with oneself as a partner, parent, family member, friend, or 
colleague) 
Psychosocial functioning (Feelings of being accepted by others, nervous to be in public, withdrawn from 
relationships)  
Psychological functioning (Feelings of depression, apathy, loneliness, suicidal thoughts. Feelings of 
irritation, anxiety, stress) 
Intimacy (Impact on sexual having desire or feeling desired, pain during sexual activity, abstaining from sex, 
fear of being rejected) 
Recreation (Interference with leisure/recreational activities (e.g., sports, do-it-yourself, playing 
instruments, scouting, hiking or outdoor life). Interference with planning of such activities) 
Impact on close relationships (Impact on relationship to partner or family member, neglect of family, poor 
understanding of disease by family) 
Cognition (Impact on concentration (e.g. at work or at school, or in leisure activities)) 
Clothing restrictions (Impact on choice of clothing (e.g. choosing clothes that do not irritate lesions, that 
cover lesions, that cover stains) 
Physical functioning* (decreased mobility, skin tightness may be associated with restrictions in exercising, 
walking, reaching out, standing, sitting, activities of daily living (e.g. housework) 
4. Satisfaction 
Satisfaction with treatment (Satisfaction with effectiveness; time spent on treatment) 
Compliance (A patient's adherence to a recommended course of treatment) 
Adverse effects of medical treatments (All types of side effects from medical treatments)  
Adverse effects of surgical treatments (All types of side effects from surgical treatments (e.g. bleeding, 
infection, contractures) 
Scarring from surgery (Scars resulting from surgery) 
Time to post-op recovery (Time to healing after surgery)  
Need for treatment and bandages (Requirements for prescribed treatment, e.g. acute treatment,  pain 
killers, topic treatment, in-hospital treatment and bandages) 
5. Symptoms 
Constitutional/prodromal (The experience of one or more symptom(s) associated with the development of 
new lesions (e.g. fatigue, fever-like sensation, headache) 
Fatigue (Physical weariness sometimes combined with mental weariness) 
Itch (Itch) 
Odour (Unpleasant odour) 
Drainage (Secretion, blood, stains, suppuration) 
6. Pain Pain 
7. Global assessments* 
Patient global assessment (Overall assessment of the disease from the perspective of the patient himself 
or herself, alone and without the influence of anyone else) 
Physician global assessment (Overall assessment of the disease from the perspective of the physician 
alone) 
